目的 探討參龍寧心膠囊聯(lián)合鹽酸索他洛爾片治療室性早搏的臨床療效。方法 選取2018年8月—2021年4月在鄭州市中心醫(yī)院就診的108例室性早搏患者，按照隨機數(shù)字表法將全部患者分為對照組和治療組，每組各54例。對照組口服鹽酸索他洛爾片，80 mg/次，1次/d。治療組在對照組治療的基礎上口服參龍寧心膠囊，2.0 g/次，3次/d。兩組患者連續(xù)治療3個月。觀察兩組的臨床療效，比較心電圖指標、心功能指標和血清指標。結(jié)果 治療后，治療組總有效率92.59%高于對照組總有效率77.78%（P＜0.05）。治療后，兩組的QT離散度、Tp-e間期、室早總數(shù)均顯著降低（P＜0.05）；治療組的QT離散度、Tp-e間期、室早總數(shù)低于對照組，差異有統(tǒng)計學意義（P＜0.05）。治療后，兩組的左室射血分數(shù)（LVEF）顯著升高，左心室收縮末內(nèi)徑（LVESD）、左心房內(nèi)徑（LAD）顯著降低（P＜0.05）；治療后治療組的LVEF高于對照組，LVESD、LAD低于對照組，差異有統(tǒng)計學意義（P＜0.05）。治療后，兩組的N前端腦鈉肽（NT-proBNP）、抗心磷脂抗體（ACA）水平顯著降低，載脂蛋白A1（ApoA1）水平顯著升高（P＜0.05）；治療后治療組的NT-proBNP、ACA水平均低于對照組，ApoA1水平高于對照組（P＜0.05）。結(jié)論 參龍寧心膠囊聯(lián)合鹽酸索他洛爾片治療室性早搏的療效確切，能減輕室性早搏癥狀，改善心功能，減輕室性早搏患者的心肌損傷。

Objective To investigate the clinical efficacy of Shenlong Ningxin Capsules combined with Sotalol Hydrochloride Tablets in treatment of ventricular premature beat. Methods Patients (108 cases) with ventricular premature beat in Zhengzhou Central Hospital from August 2018 to April 2021 were divided into control and treatment groups according to random number table method, and each group had 54 cases. Patients in the control group were po administered with Sotalol Hydrochloride Tablets, 80 mg/time, once daily. Patients in the treatment group were po administered with Shenlong Ningxin Capsules on the basis of the control group, 2.0 g/time, three times daily. Patients in two groups were treated for 3 months. After treatment, the clinical efficacies were evaluated, and electrocardiographic index, cardiac function, and serum index in two groups were compared. Results After treatment, the total effective rate of the treatment group (92.59%) was higher than that of the control group (77.78%) (P < 0.05). After treatment, the QT dispersion, Tp-e interval, and total number of ventricular premature beats in two groups were significantly decreased (P < 0.05). The QT dispersion, Tp-e interval, and total number of ventricular premature beats in the treatment group were lower than those in the control group (P < 0.05). After treatment, the LVEF in two groups were significantly increased, but the LVESD and LAD in two groups were significantly decreased (P < 0.05). After treatment, the LVEF in the treatment group was higher than that in the control group, but the LVESD and LAD were lower than that in the control group (P < 0.05). After treatment, the levels of NT-proBNP and ACA in two groups were significantly decreased, but the level of ApoA1 in two groups were significantly increased (P < 0.05). After treatment, the levels of NT-proBNP and ACA in the treatment group were lower than those in the control group, but the level of ApoA1 in the treatment group was higher than those in the control group (P < 0.05). Conclusion Shenlong Ningxin Capsules combined with Sotalol Hydrochloride Tablets is effective in treatment of ventricular premature beat, can reduce the symptoms of ventricular premature beat, improve cardiac function, and reduce the myocardial injury.

R972

河南省醫(yī)學科技攻關計劃聯(lián)合共建項目(LHGJ20191043)